Details for New Drug Application (NDA): 210203
✉ Email this page to a colleague
NDA 210203 describes CAPECITABINE, which is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms, Dr Reddys, Eugia Pharma, Hetero Labs Ltd V, Hikma, MSN, Reliance Life, Rising, Shilpa, Sun Pharm, Teva Pharms Usa, and Teyro Labs, and is included in fourteen NDAs. It is available from eighteen suppliers. Additional details are available on the CAPECITABINE profile page.
The generic ingredient in CAPECITABINE is capecitabine. There is one drug master file entry for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
The generic ingredient in CAPECITABINE is capecitabine. There is one drug master file entry for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
Summary for 210203
| Tradename: | CAPECITABINE |
| Applicant: | Hetero Labs Ltd V |
| Ingredient: | capecitabine |
| Patents: | 0 |
Pharmacology for NDA: 210203
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 210203
Suppliers and Packaging for NDA: 210203
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CAPECITABINE | capecitabine | TABLET;ORAL | 210203 | ANDA | Camber Pharmaceuticals, Inc. | 31722-774 | 31722-774-60 | 60 TABLET, FILM COATED in 1 BOTTLE (31722-774-60) |
| CAPECITABINE | capecitabine | TABLET;ORAL | 210203 | ANDA | Camber Pharmaceuticals, Inc. | 31722-775 | 31722-775-12 | 120 TABLET, FILM COATED in 1 BOTTLE (31722-775-12) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Mar 5, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Mar 5, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
